Preferred Label : Integrin Alpha V Beta 3-targeting Protein ACT50;
NCIt definition : An integrin alpha V beta 3-targeting protein, with potential pro-apoptotic, anti-angiogenic
and antineoplastic activities. Upon administration, integrin alpha V beta 3-targeting
protein ACT50 targets the cell surface receptor integrin alpha V beta 3, at a site
other than the ligand-binding site, expressed on angiogenic endothelial cells (aECs)
and cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME), and
recruits and activates caspase 8. This leads to the apoptosis of alpha V beta 3-expressing
aECs and CAFs, and may inhibit tumor growth, angiogenesis, and metastasis. Alpha V
beta 3 integrin, a cell adhesion and signaling receptor, is expressed on the surface
of aECs, CAFs and some tumor cells and has been associated with increased proliferation,
migration and invasion of tumor cells.;
Drug name : ProAgio;
Molecule name : ACT-50; ACT 50;
NCI Metathesaurus CUI : CL1778624;
Origin ID : C186277;
UMLS CUI : C5667048;
Semantic type(s)
- concept_is_in_subset
- has_target
